TY - JOUR
T1 - High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma
AU - Ye, Lei
AU - Santarpia, Libero
AU - Cote, Gilbert J.
AU - El-Naggar, Adel K.
AU - Gagel, Robert F.
N1 - Funding Information:
We are grateful to the Kosberg Foundation and to John and Jennifer Ball, who generously supported this research, and to the Cancer Genomics Core Resource at The University of Texas, M. D. Anderson Cancer Center, which is supported by National Cancer Institute Grant CA16672.
PY - 2008/11
Y1 - 2008/11
N2 - Context: Activating mutations in the RET protooncogene have been demonstrated in multiple endocrine neoplasia 2 and sporadic medullary thyroid carcinoma (MTC). However, the complete genetic etiology underlying MTC tumorigenesis remains unclear. Objective: Our objective was to define more precisely the chromosomal regions and uncover novel genes associated with MTC tumorigenesis. Design and Setting: In this study, we used high resolution array-based comparative genomic hybridization to define tumor-associated copy number alterations (CNA) in 30 primary MTCs: 20 sporadic tumors (50% of which harbored RET mutation), and 10 hereditary. Results: We identified 98 CNA, including 76 genomic allelic losses, two gains, and 20 copy number variations associated with MTC. Across sporadic and hereditary groups, there was a similar and overlapping pattern of predominant allelic loss. Therewere 29 regions containing at least 30% CNA in the 30 tumor samples. The most frequent allelic loss occurred in four loci, 7q36.1, 12p13.31, 13q12.11, and 19p13.3-11. No regions were found to be uniquely altered in the hereditary tumors. There were 21 CNA specific to sporadic MTC, with loss of 11q23.3 uniquely altered in RET negative tumors. Pathway analysis found cellular growth and proliferation as the most significant overall target, and cell death as the most significant pathway targeted in sporadic MTC. Conclusions: Our findings underscore the importance of candidate tumor suppressor genes together with RET alterations in MTCs. Despite of RET status, all MTC might share similar oncogenetic mechanisms. Dysfunction of cell proliferation and cell death may both be involved in MTC tumorigenesis.
AB - Context: Activating mutations in the RET protooncogene have been demonstrated in multiple endocrine neoplasia 2 and sporadic medullary thyroid carcinoma (MTC). However, the complete genetic etiology underlying MTC tumorigenesis remains unclear. Objective: Our objective was to define more precisely the chromosomal regions and uncover novel genes associated with MTC tumorigenesis. Design and Setting: In this study, we used high resolution array-based comparative genomic hybridization to define tumor-associated copy number alterations (CNA) in 30 primary MTCs: 20 sporadic tumors (50% of which harbored RET mutation), and 10 hereditary. Results: We identified 98 CNA, including 76 genomic allelic losses, two gains, and 20 copy number variations associated with MTC. Across sporadic and hereditary groups, there was a similar and overlapping pattern of predominant allelic loss. Therewere 29 regions containing at least 30% CNA in the 30 tumor samples. The most frequent allelic loss occurred in four loci, 7q36.1, 12p13.31, 13q12.11, and 19p13.3-11. No regions were found to be uniquely altered in the hereditary tumors. There were 21 CNA specific to sporadic MTC, with loss of 11q23.3 uniquely altered in RET negative tumors. Pathway analysis found cellular growth and proliferation as the most significant overall target, and cell death as the most significant pathway targeted in sporadic MTC. Conclusions: Our findings underscore the importance of candidate tumor suppressor genes together with RET alterations in MTCs. Despite of RET status, all MTC might share similar oncogenetic mechanisms. Dysfunction of cell proliferation and cell death may both be involved in MTC tumorigenesis.
UR - http://www.scopus.com/inward/record.url?scp=57349167652&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57349167652&partnerID=8YFLogxK
U2 - 10.1210/jc.2008-0912
DO - 10.1210/jc.2008-0912
M3 - Article
C2 - 18765511
AN - SCOPUS:57349167652
SN - 0021-972X
VL - 93
SP - 4367
EP - 4372
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 11
ER -